Pharma's plastic prescription bottle problem gets a paper solution
Have you ever stopped to think about what happens to those little orange pill bottles after you finish your prescription? Every year, around 200 billion of these bottles are produced worldwide, and sadly most of them end up in landfills. In the U.S. alone, about 4 to 5 billion plastic pill bottles are thrown away each year.
That's enough plastic to circle the Earth multiple times.
While they might seem harmless, these bottles contribute significantly to the growing plastic pollution crisis because they're often not recycled properly.
Join The FREE "CyberGuy Report": Get my expert tech tips, critical security alerts and exclusive deals, plus instant access to my free "Ultimate Scam Survival Guide" when you sign up.
Plastic has become the go-to material for packaging, including in medicine, because it's cheap, durable and easy to produce. However, the environmental cost is huge, and the pharmaceutical industry has struggled to find a sustainable alternative.
Enter the Tully Tube, a revolutionary new pill bottle made mostly from 100% sustainably sourced paper. Developed by Parcel Health, this isn't just any paper bottle. It's the first one to meet the strict U.S. FDA regulations for food-contact packaging, making it safe to use for prescription medications.
What makes the Tully Tube really impressive is how it balances sustainability with practicality. The body of the bottle is made from recyclable and compostable paper, which means it can break down naturally instead of piling up in landfills. The cap, which needs to be child-resistant for safety, is still made from plastic but uses recycled materials to reduce its environmental impact.
You might be wondering how a paper bottle can protect pills from moisture, heat or damage during shipping. The Tully Tube uses a clever three-layer construction. It's coated with a food-safe compostable layer that keeps water and humidity out, ensuring your medication stays fresh and effective.
When it's time to toss the bottle, a patented pull tab makes it easy to separate the paper body from the plastic cap and neck. This means the paper part can be composted or recycled, while the plastic pieces can be recycled separately. It's a simple but smart way to make sure every part of the bottle is handled properly at the end of its life.
One of the biggest hurdles for sustainable packaging is cost. Fortunately, the Tully Tube is priced competitively with traditional plastic bottles, so pharmacies don't have to pay more to go green. Plus, because the paper surface is easier and cheaper to print on, pharmacies and pharmaceutical companies can customize the bottles with logos, designs or even characters to make the packaging more engaging for customers.
From an environmental perspective, the Tully Tube reduces carbon emissions by about 30% compared to plastic bottles. That's a significant cut in greenhouse gases, especially when you consider the billions of bottles used every year.
UVA Health is already leading the way by rolling out Tully Tubes across its system. This move is expected to eliminate millions of plastic bottles from their waste stream, showcasing how sustainable packaging can work even in industries with strict safety and regulatory standards. Their example proves that eco-friendly alternatives aren't just theoretical, they're ready for real-world use today.
The Tully Tube may seem like a small innovation, but it has the potential to make a huge environmental difference. It challenges the longstanding reliance on plastic in the pharmaceutical industry by offering a practical, safe and sustainable alternative. As more hospitals and pharmacies consider adopting this new packaging, the impact could be enormous.
Would you be open to using a paper pill bottle instead of the traditional plastic one? Why or why not? Let us know by writing us at Cyberguy.com/Contact.
For more of my tech tips and security alerts, subscribe to my free CyberGuy Report Newsletter by heading to Cyberguy.com/Newsletter.
Follow Kurt on his social channels:
Answers to the most-asked CyberGuy questions:
New from Kurt:
Copyright 2025 CyberGuy.com. All rights reserved.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held yesterday on June 5, 2025 (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 17, 2025 (the "Circular") to its Shareholders were approved. Results of the matters voted on at the Meeting are set out below. Election of Directors Spectral's seven director nominees were elected: Nominee Votes For (percent) Votes Withheld (percent) Jan D'Alvise 99.78% 0.22% Jun Hayakawa 99.79% 0.21% Chris Seto 89.39% 10.61% William Stevens 99.50% 0.50% Paul Walker 97.67% 2.33% David W. Feigal, Jr. 99.67% 0.33% Cristiano Franzi 99.78% 0.22% Appointment of Auditors MNP LLP, Chartered Accountants, was re-appointed as auditor of Spectral. Votes For: 99.95% Votes Withheld: 0.05% About Spectral Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX'). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's FDA cleared Endotoxin Activity Assay (EAA™), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively over 360,000 times to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year. The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis The trial methods are detailed in 'Bayesian methods: a potential path forward for sepsis trials'. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit statement Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the company's ability to raise capital and the availability of funds and resources to pursue R&D projects, the recruitment of additional clinical trial sites, the rate of patient enrollment, the successful and timely completion of clinical studies, the success of Baxter's commercialization efforts, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For further information, please contact: Ali MahdaviCapital Markets & Investor RelationsSpinnaker Capital Markets Inc.416-962-3300am@
Business Wire
2 days ago
- Business Wire
OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
NEW YORK--(BUSINESS WIRE)-- OS Therapies Inc. (NYSE-A: OSTX) ('OS Therapies' or 'the Company'), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative medicine therapies for serious or life-threatening conditions and provide sponsors with various benefits, including eligibility for an accelerated Biologics License Application (BLA) review. OST-HER2 has already received Rare Pediatric Disease Designation (RPDD), Orphan Drug Designation (ODD) and Fast Track Designation (FTD) for osteosarcoma from the U.S. FDA. If OST-HER2 receives a conditional BLA via Accelerated Review prior to September 30, 2026, the Company will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent publicly disclosed PRV sale, valued at $155 million, occurred in May 2025. The Company is awaiting feedback by mid-June 2025 from a Type D meeting with FDA regarding the statistical analysis plan to be used in an End of Phase 2 meeting for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. Upon receipt of the Type D Meeting feedback, the Company intends to promptly request the End of Phase 2 meeting with FDA in which it will be seek agreement to allow it to begin a rolling BLA submission in the third quarter of 2025. The grant of the RMAT designation in the third quarter of 2025 complements the company's parallel efforts in other major markets, including Europe and the United Kingdom, where the company plans to seek EMA PRIME Designation and Conditional Market Access (CMA) applications. In parallel to regulatory engagement and market access planning for OST-HER2, the Company is preparing for the late stage clinical development of other pipeline candidates. As such, the Company is well positioned for sustained growth across multiple therapeutic modalities. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company has demonstrated positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a BLA to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Yahoo
4 days ago
- Yahoo
Allulose Market Size with 6.5% CAGR, Reaching USD 463.17 Mn by 2031
The allulose market is growing rapidly due to rising demand for low-calorie, sugar-free alternatives amid increasing health awareness. Allulose, a rare sugar with minimal calories, is gaining traction in food and beverage products like baked goods, dairy, and beverages. The U.S. FDA's exclusion of allulose from added sugar labeling has further boosted adoption. Key players include Tate & Lyle, Ingredion, CJ CheilJedang, Cargill, and Samyang Genex. US & Canada, June 04, 2025 (GLOBE NEWSWIRE) -- According to a new research report from The Insight Partners, the global allulose market is witnessing significant growth owing to favorable government guidelines and incentives supporting the use of low-calorie sweeteners, and the growing popularity of the ketogenic diet. The allulose market analysis considers several consumer preferences and demographics that are expected to contribute to the market's strength in the coming years. The report runs an in-depth analysis of market trends, key players, and future opportunities. To explore the valuable insights in the Allulose Market report, you can easily download a sample PDF of the report – Overview of Report Findings Market Growth: The allulose market value is expected to reach US$ 463.17 million by 2031 from US$ 280.22 million in 2024; it is estimated to register a CAGR of 6.5% during the forecast period. Allulose, i.e., D-psicose or D-allulose, is a rare sugar found in minuscule quantities in figs, raisins, and maple syrup. It offers approximately 70% of the sweetness of sucrose but with minimal caloric content. This attribute makes it an attractive option for individuals looking to reduce sugar intake without compromising on taste. Expansion of the allulose market is particularly evident in regions such as North America and Asia Pacific, where health-conscious consumers are actively seeking sugar substitutes. In North America, regulatory approvals and a growing awareness of health issues related to excessive sugar consumption bolster the market. Favorable Government Guidelines and Incentives: Governments across the world have been providing clear guidelines and incentives that encourage the use of allulose as a low-calorie sweetener. In the US, the Food and Drug Administration (FDA) has exempted allulose from being counted as added or total sugars on nutrition labels, along with recognizing it as a Generally Recognized As Safe (GRAS) substance. Such regulatory support facilitates its incorporation into a wide range of food products and beverages, and reassures manufacturers and consumers of its safety and efficacy. Similarly, countries such as South Korea have approved allulose for use in various food applications, leading to increased production and availability. These supportive policies align with global health initiatives aimed at reducing sugar consumption, thereby driving demand for healthier alternatives such as allulose. Growing Popularity of Ketogenic Diet: The rising popularity of the ketogenic diet creates a strong growth opportunity for the allulose market as it prompts the consumption of low-carb, low-calorie sweeteners that don't lead to blood sugar spikes. Since keto followers aim to reduce carbohydrate intake drastically, they avoid traditional sugars, making allulose and other low-calorie sweeteners attractive alternatives due to their sugar-like taste and minimal impact on blood glucose. Unlike some artificial sweeteners that can have an aftertaste or cause digestive issues, allulose closely mimics the flavor and texture of real sugar, which makes it especially appealing for keto-friendly recipes and packaged foods. As more consumers adopt keto and other low-carb lifestyles for weight management or health reasons, manufacturers are incorporating allulose into products such as baked goods, beverages, and snacks to meet this demand. This shift in dietary preferences is driving innovation and expanding the presence of allulose in mainstream food markets. Geographical Insights: In 2024, North America led the allulose market with a substantial revenue share, followed by Europe and Asia Pacific. Further, Asia Pacific is expected to register the highest CAGR during the forecast period. For Detailed Allulose Market Insights, Visit: Market Segmentation Based on form, the allulose market is segmented into powder and liquid. The powder segment held a larger market share in 2024. By application, the allulose market is segmented into food and beverages, pharmaceuticals and nutraceuticals, and others. The food and beverages segment dominated the market in 2024. The allulose market, by region, is segmented into North America, Europe, APAC, the Middle East and Africa, and South and Central America. Stay Updated on The Latest Allulose Market Trends: Competitive Strategy and Development Key Players: Tate and Lyle; Ingredion; SAMYANG CORPORATION; G-Sweetz; Heartland Food Products Group LLC; Pyure; Nutrishus Brands Inc.; Whole Earth Brands Inc.; Anderson Global Group, LLC; Matsutani Chemical Industry Co., Ltd.; Cargill, Incorporated; Apura Ingredient; PALMER HOLLAND; The Scoular Company; and The Truvía Company LLC are among the prominent players operating in the allulose market. Trending Topics: Natural sweeteners, stevia, etc. Global Headlines on Allulose Liquid I.V. has expanded its portfolio with the launch of a "sugar-free" hydration multiplier that contains allulose instead of the glucose found in its original formula. Purchase Premium Copy of Global Allulose Market Size and Growth Report (2021-2031) at: Conclusion The demand for allulose is rapidly increasing due to rising consumer awareness of health and wellness, especially in relation to sugar intake and its role in driving the development of conditions such as obesity and diabetes. As a rare sugar with nearly 70% of the sweetness of sucrose and only a fraction of the calories, allulose offers a compelling alternative to traditional sugars and some other sugar substitutes. It has a similar taste and texture to sugar, making it appealing for manufacturers aiming to reduce added sugars in products without compromising flavor. Regulatory approvals in markets such as the US also encourage its incorporation in packed food and baked products, among others. In addition, continuous progress in concepts such as keto, low-carb, and diabetic-friendly diets further fuels consumer and industry interest in allulose. Thus, with food and beverage companies' emphasis on meeting the burgeoning demand for healthier products, allulose is becoming a key ingredient in reformulations and new product launches. The report from The Insight Partners provides information on several stakeholders—including allulose manufacturers, suppliers, and distributors—along with valuable key insights on how to successfully navigate this evolving market landscape and unlock new opportunities. Talk to Us Directly: Trending Related Reports: Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: Phone: +1-646-491-9876 Home - in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
